Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, cephalosporin tablets, and other oral solid-dosage-form antibiotics. It also provides system specific medicines for various therapeutic areas, such as cardiovascular systems; anti-HBV, anti-allergic, and digestive systems; urinary systems; anti-hypertensive, antihyperlipidemic, and antiviral; and endocrine system drugs. The company was founded in 1995 and is headquartered in Wan Chai, Hong Kong.
Research context
Dawnrays Pharmaceutical (Holdings) Limited appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Dawnrays Pharmaceutical (Holdings) Limited is currently in a long term uptrend where the price is trading 32.8% above its 200 day moving average.
From a valuation standpoint, the stock is 98.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.
Dawnrays Pharmaceutical (Holdings) Limited's total revenue rose by 6.5% to $489M since the same quarter in the previous year.
Its net income has increased by 23.5% to $130M since the same quarter in the previous year.
Finally, its free cash flow grew by 166.0% to $69M since the same quarter in the previous year.
Based on the above factors, Dawnrays Pharmaceutical (Holdings) Limited gets an overall score of 5/5.